Immatics NV is a clinical-stage biopharmaceutical company that is based in the Netherlands. The Company is focused on the discovery and development of T-Cell eceptors with the goal of enabling a robust and specific T-Cell response against these targets. The Company develops targeted immunotherapies with an emphasis on treating solid tumors through two distinct therapeutic modalities: Adoptive Cell Therapies (ACT) and antibody-like TCR Bispecifics (TCER). Its wholly owned pipeline comprises of eight therapeutic programs, of which four are in clinical trials, including IMA201 (MAGEA4/8), IMA202 (MAGEA1) and ACTolog IMA 101 (Multi-target pilot trial) for solid cancers and IMA203 (PRAME) for hematological and solid cancers, as well as four are in preclinical development, including IMA204 (COL6A3) and IMA401 (Cancer testis antigen) for solid cancers, and ACTallo IMA301 (Cancer testis antigen) and IMA402 (Cancer testis antigen) for hematological and solid cancers.
Growing
The company is in a growing phase, with the latest annual income totaling USD 56.02M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 56.02M.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD .
Fairly Valued
The company’s latest PE is -13.03, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 101.84M shares, decreasing 14.61% quarter-over-quarter.
Held by ETHSX
Star Investor ETHSX holds 8.17K shares of this stock.